Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Protalix BioTherapeutics (PLX) over the last 11 years, with Q3 2025 value amounting to $8.1 million.

  • Protalix BioTherapeutics' Accumulated Expenses changed N/A to $8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.1 million, marking a year-over-year change of. This contributed to the annual value of $9.6 million for FY2024, which is 620.49% up from last year.
  • Protalix BioTherapeutics' Accumulated Expenses amounted to $8.1 million in Q3 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Accumulated Expenses peaked at $9.6 million during Q4 2024, and registered a low of $7.3 million during Q2 2025.
  • Its 3-year average for Accumulated Expenses is $8.7 million, with a median of $9.0 million in 2023.
  • Data for Protalix BioTherapeutics' Accumulated Expenses shows a peak YoY increase of 620.49% (in 2024) and a maximum YoY decrease of 620.49% (in 2024) over the last 5 years.
  • Over the past 3 years, Protalix BioTherapeutics' Accumulated Expenses (Quarter) stood at $9.0 million in 2023, then increased by 6.2% to $9.6 million in 2024, then fell by 15.07% to $8.1 million in 2025.
  • Its Accumulated Expenses stands at $8.1 million for Q3 2025, versus $7.3 million for Q2 2025 and $9.3 million for Q1 2025.